MedTrace Logo

Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis

NCT05065905 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2024-01-25

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to assess the safety and efficacy of interferon-gamma by subcutaneous injection in complex treatment of patients with co-infection of HIV and pulmonary tuberculosis and to determine the rational of its use.

Conditions

  • HIV Coinfection
  • Aids/Hiv Problem
  • Tuberculosis, Pulmonary
  • Human Immunodeficiency Virus
  • Lentivirus Infections
  • RNA Virus Infections

Interventions

DRUG

Interferon-Gamma

received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein

Sponsors & Collaborators

  • North-Western State Medical University named after I.I.Mechnikov

    collaborator OTHER

  • SPP Pharmaclon Ltd.

    lead INDUSTRY

Principal Investigators

  • Vladimir Shmelev, Doctor · SPP Pharmaclon Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-19
Primary Completion
2006-03-29
Completion
2006-04-06

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05065905 on ClinicalTrials.gov